The rio trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting hiv-specific broadly neutralising antibodies (bnabs) in participants diagnosed with recent hiv infection—study protocol for a two-stage randomised phase ii trial

HIGHLIGHTS

• who: Ming Jie Lee from the Disease, Imperial College London, UK for Pathogen Research, University of have published the article: The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infectionu2014study protocol for a two-stage randomised phase II trial, in the Journal: (JOURNAL)
• what: The RIO trial aims to investigate the use of a novel combination of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.